acute myocardial infact
Conditions
Interventions
Drug :Before PCI operation 4 pill will be given and patients will receive 2 pill each time, 3 time per day for 30 days
Placebo :Before PCI operation 4 placebo pill will be given and patients will receive 2 placebo pill each time, 3 time per day for 30 days
Sponsors
Second Affiliated Hospital of Second Military Medicial University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. aged 18-75 years; 2. persisitant chest pain (at least 30min and not exceed 24 hours); 3. ST segment elevation great than or equal to 0.1 mm on two neighbouring limb leads or great than or equal to 0.2 mm on two neighbouring precordial leads, or new left bundle branch block; 4. serum cTnT levels exceed 99% upper limit of the reference range or CK-MB levels great than or equal to three time of normal value; 5. Agree to receive PCI operation.
Exclusion criteria
Exclusion criteria: 1. SBP less than 80mmHg; 2. TIMI of Culprit vessels reach 3 by PCI operation without the need of intervention; 3. patients receiving CPR and IABP within 1 month; 4. Dignosed myocardial infact within 1 month; 5. severe heart dysfunction with LVEF less than 30%, or NYHA or Killip levels more than 3; 6. suspected aortic dissection and patients receiving CABG operation; 7. history of cerebral hemorrhage and ischemic stroke within 3 months; 8. patients with hypertrophic obstructive cardiomyopathy, moderate or severe aortic stenosis or regurgitation; 9. severe arrhythmia (atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, type II degree II atrioventricular block); 10. QT/QTc interval prolongation(QTc interval more than 450ms),or with a history of leading to the disease (TdP) including heart failure, hypokalemia and familial long QT syndrome, or drugs which could prolong QTc interval; 11. severe infection; 12. moderate to severe anemia (HGB less than 90g/l); 13. pregnant or lactating women; 14. patients receiving operation within 4 weeks or with severe tendency of haemorrhage; 15. anyone who also participate in other trials recently or within 1 month; 16. hypersensitivity to known components of the tested drug; 17. diagnosed with other diseases with poor prognosis (for example metastatic carcinoma) or increasing the risk of serious adverse events; 18. severe advancing diseases with short life span; 19. other conditions which the researchers commit to unfit for such trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| corrected TIMI scores;one-year MACE(Major adverse cardiac events); | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery of ST segement after PCI operation;serum cTnT and CK-MB peak levels;LVEDV POD1 and 30;LVEF POD1 and 30;serum NT-proBNP POD1 and 30;CFR evaluated by transthoracic echocardiography POD1 and 30;30/90/180 day MACE(Major adverse cardiac events); | — |
Countries
China
Contacts
Public ContactRu DING
Second Affiliated Hospital of Second Military Medicial University
Outcome results
None listed